RESUMEN
Introducción: Las guías de la National Comprehensive Cancer Network (NCCN) establecen criterios para solicitud de estudios BRCA1/2. La identificación de pacientes portadores de variantes patogénicas, constituye una oportunidad para dirigirlos hacia programas de cuidado específicos. Objetivo: Analizar si los criterios para la solicitud de estudio genético BRCA1 y 2, cumplen con los criterios indicados en las guías de la NCCN 2019. Describir las características de los pacientes con mutaciones patogénicas para BRCA 1/2; estrategias de prevención y reducción de riesgo llevadas a cabo. Resultados: Se solicitó el estudio a 103 pacientes, de las cuales 101 (98%) cumplían con al menos 1 criterio acorde a NCCN 2019 y realizaron el estudio 77 pacientes (76%). Obtuvimos 15 resultados positivos para una mutación patogénica en BRCA 1y 2 (19.4%), 61 resultados negativos (79.22%) y 1 variante de significado incierto (VUS) en BRCA1 (1.29%). El 46.66 % de las pacientes con mutación patogénica (PMP) eligió al menos una estrategia quirúrgica de disminución de riesgo. Conclusiones: El 98% de los pacientes a quienes se les solicito el estudio cumplían con al menos un Criterio de las Guías NCCN 2019.El hallazgo de 19.4% de mutaciones, probablemente se deba a la correcta selección de pacientes.
Introduction: National Comprehensive Cancer Network Guidelines (NCCN) establish BRCA 1/2 testing criteria. Identification of mutations carriers gives an opportunity to direct them towards specific care programs. Objective: Analyze whether the BRCA 1/2 testing criteria met the NCCN 2019 guidelines criteria. To describe the characteristics of BRCA 1/2 pathogenic mutations carriers, risk reduction and prevention strategies carried out. Results: The study was requested to 103 patients, 101 patients (98%) met at least one NCCN 2019 testing criteria and 77 patients (76%) did the test. We obtained 15 positive results for a BRCA 1/2 pathogenic mutation (19.4%), 61 negative results (79.22%) and 1 BRCA 1 variant of uncer- tain significance (VUS) (1.29%). The 46.66% of patients with a pathogenic mutation chose at least one surgical risk reducing strategy. Conclusions: Al least one NCCN 2019 testing criteria was fulfilled by the 98 % of the patients to whom the test was requested. Probably due to the correct patient selection we found 19.4% mutations in our study.
Asunto(s)
Neoplasias , Pacientes , Estrategias de Salud , GenéticaRESUMEN
@#This study was aimed to design the first dual-target small-molecule inhibitor co-targeting poly (ADP-ribose) polymerase-1 (PARP1) and bromodomain containing protein 4 (BRD4), which had important cross relation in the global network of breast cancer, reflecting the synthetic lethal effect. A series of new BRD4 and PARP1 dual-target inhibitors were discovered and synthesized by fragment-based combinatorial screening and activity assays that together led to the chemical optimization. Among these compounds, 19d was selected and exhibited micromole enzymatic potencies against BRD4 and PARP1, respectively. Compound 19d was further shown to efficiently modulate the expression of BRD4 and PARP1. Subsequently, compound 19d was found to induce breast cancer cell apoptosis and stimulate cell cycle arrest at G1 phase. Following pharmacokinetic studies, compound 19d showed its antitumor activity in breast cancer susceptibility gene 1/2 (BRCA1/2) wild-type MDA-MB-468 and MCF-7 xenograft models without apparent toxicity and loss of body weight. These results together demonstrated that a highly potent dual-targeted inhibitor was successfully synthesized and indicated that co-targeting of BRD4 and PARP1 based on the concept of synthetic lethality would be a promising therapeutic strategy for breast cancer.
RESUMEN
BACKGROUND: Hereditary breast and ovarian cancer syndrome (HBOC) is caused by pathogenic variants in BRCA and other cancer-related genes. We analyzed variants in BRCA gene and other cancer-related genes in HBOC patients to evaluate the clinical validity of next-generation sequencing (NGS) multi-gene panel testing. METHODS: The BRCA1/2 NGS testing was conducted for 262 HBOC patients. Multiplex ligation-dependent probe amplification and direct Sanger sequencing were performed for confirmation. Multi-gene panel testing was conducted for 120 patients who did not possess BRCA1/2 pathogenic variants but met the National Comprehensive Cancer Network criteria. RESULTS: Pathogenic variants in BRCA1/2 were detected in 30 HBOC patients (11.5%). Additionally, four out of the 120 patients possessed pathogenic variants by multi-gene panel testing (3.3%): MSH2 (c.256G>T, p.Glu86*), PMS2 (c.1687C>T, p.Arg563*), CHEK2 (c.546C>A, p.Tyr182*), and PALB2 (c.3351-1G>C). All the four patients had a family history of cancer. CONCLUSIONS: Multi-gene panel testing could be a significant screening tool for HBOC patients, especially for those with a family history of cancer.
Asunto(s)
Humanos , Síndrome de Cáncer de Mama y Ovario Hereditario , Tamizaje Masivo , Reacción en Cadena de la Polimerasa MultiplexRESUMEN
Objective: To explore the possibility of prophylactic nipple-sparing mastectomy and immediate reconstruction in healthy Chinese women with BRCA1/BRCA2 germline mutation. Methods: From January 2018 to February 2019, three healthy Chinese women with a BRCA1/ BRCA2 germline pathogenic mutation were treated at the Department of Breast Surgery, Peking University International Hospital (2 cases of BRCA1 mutation and 1 case of BRCA2 mutation); these three women (aged 34-36 years) had a strong family history of breast cancer. Thus, they underwent prophylactic nipple-sparing mastectomy and immediate reconstruction. Results: The operations were successfully completed, and no complications occurred. After a median 18-month follow-up, no breast cancer occurred in the three women; they were satisfied with the reconstructed breast's shape, and their anxiety also significantly reduced. Conclusions: Healthy Chinese women with a BRCA1/ BRCA2 germline mutation and a strong family history of breast cancer can possibly consider prophylactic nipple-sparing mastectomy and immediate reconstruction as options.
RESUMEN
Resumen: ANTECEDENTES: El carcinoma intraepitelial tubárico seroso es una lesión precursora del carcinoma invasivo de las trompas de Falopio que con frecuencia se diagnostica en el contexto de una salpingooforectomía bilateral profiláctica por patología ginecológica benigna. CASO CLÍNICO: Paciente nulípara, de 51 años, con cuadro clínico de dolor abdominal y elevación de marcadores tumorales CA-125 y CA-19.9, diagnosticada con útero polimiomatoso y sospecha de endometrioma en el ovario derecho. Después de la histerectomía subtotal con anexectomía bilateral, el estudio histológico de la pieza tubárica extirpada reportó focos microscópicos de carcinoma intraepitelial tubárico seroso, sin signos de invasión estromal. Por los hallazgos se solicitaron pruebas de imagen mamarias y el estudio genético de mutación BRCA 1 y 2. CONCLUSIÓN: La salpingooforectomía bilateral profiláctica es un procedimiento que reduce el riesgo de carcinomas peritoneales, tubáricos y serosos de ovario. Las pacientes con carcinoma intraepitelial tubárico seroso deben tener seguimiento basado en controles ecográficos, pruebas de imagen mamarias, determinación de marcadores tumorales y estudios genéticos, debido a su asociación con mutaciones en los genes BRCA 1 y 2.
Abstract: BACKGROUND: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion of invasive high-grade tubal and serous carcinoma of the ovary, frequently diagnosed in the context of prophylactic bilateral salpingoophorectomy for benign gynecological pathology. The objective of this work is to carry out a literature review on the most relevant aspects of the follow-up of this injury, after its incidental diagnosis in gynecological surgery. CLINICAL CASE: A 51-year-old nulliparous patient who, in the context of a clinical situation of abdominal pain with elevation of tumor markers CA125 and CA19.9, was diagnosed with polymomatous uterus and suspected endometrioma in the right ovary. After a subtotal hysterectomy with bilateral adnexectomy, the histological study of the excised tubal specimen found microscopic foci of STIC without signs of stromal invasion. Given this finding, breast imaging tests and a genetic study of the BRCA 1/2 mutation was requested. CONCLUSION: Prophylactic bilateral salpingoophorectomy in gynecological surgery is a procedure that can reduce the risk of developing peritoneal, tubal, and serous ovarian carcinomas. Patients diagnosed with STIC should be subsidiaries of follow-up based on ultrasound controls, mammary imaging tests, tumor markers, and genetic studies, due to their association in many cases with mutations in the BRCA 1/2 genes. It is necessary to establish a series of standardized clinical protocols for the management of patients with STIC and to continue advancing our understanding of this pathology and its subsequent evolution to high-grade serous carcinoma.
RESUMEN
Introducción Si bien el cáncer de mama hereditario representa entre el 5-10% del total de los cánceres de mama, es importante la detección de pacientes portadoras de mutaciones patogénicas en genes brca1/2 y otros genes relacionados con el cáncer de mama ya que esta información permitirá tomar conductas adecuadas de prevención y/o tratamiento tanto en la paciente portadora como en sus familiares. Objetivo Llevar a cabo un análisis retrospectivo de 106 pacientes que realizaron estudios genéticos para genes brca1/2 y otros genes relacionados con el cáncer de mama. Resultados Del total de 106 pacientes, encontramos: 17 (16,03%) con mutación patogénica; 38 (35,85%) con vus (Variantes de significado incierto) informadas en el reporte original; y 51 (48,11%) con estudios negativos. De los 38 informes con vus, 7 (6,6%) fueron reclasificadas como vus verdaderas a junio de 2018. De las 17 mutaciones patogénicas encontradas, 16 correspondieron a mutaciones en los genes brca1/2 (15,09%) y 1 a mutación en el chek2 (3,77%). Conclusiones Los estudios genéticos de predisposición en cáncer de mama son, en la actualidad, una herramienta fundamental para la atención multidisciplinaria de la paciente de alto riesgo en un consultorio de patología mamaria. Es un deber del mastólogo pensar en la indicación de un estudio genético de predisposición al cáncer de mama y derivar al genetista para identificar correctamente al paciente que se va a beneficiar de esta información
Introduction Although hereditary breast cáncer represents 5-10% of all breast cancers, it is important to detect patients carrying pathogenic mutations in brca1/2 genes and other genes related to breast cáncer as this information will allow take appropriate prevention and / or treatment behaviors in both the patient carrier and their family members. Objective To make a retrospective analysis of 106 patients who carried out genetic studies for brca1/2 genes and other genes related to breast cancer. Results From 106 patients we found 17 (16.03%) with pathogenic mutations, 38 (35.85%) with vus (variant of unknown significance) in the original report, and 51 (48.11%) negatives. From 35 vus, we reclasified as true vus only 7 (6,6%) in June 2018. From 17 pathogenic mutations in 106 patients studied (16.03%), we found 16 in the brca1/2 genes (15.09%) and 1 mutation in chek2 (3.77%). Conclusions Genetic predisposition tests in breast cáncer are a fundamental tool for multidisciplinary care of the high-risk patient in a breast center query. The mastologist has to think in the first place about the indication of a genetic testing ofbreast cancer predisposition, and refer to the geneticist for a prompt consultation for patients benefit
Asunto(s)
Neoplasias de la Mama , Predisposición Genética a la Enfermedad , GenesRESUMEN
Objective To investigate the knowledge and willingness of genetic counseling and testing in blood relatives of breast cancer patients.Methods A total of 922 blood relatives of breast cancer patients finished our questionnaire.Data were devided into different groups according to age,family history of tumor for statistical analysis.Results Most of the respondents were unaware of genetic counseling and genetic testing.However,after a brief introduction,major of them were willing to accept genetic counseling,breast cancer risk evaluation and screening.Specifically,79.8％ of them were willing to accept genetic counseling,and 62.3％ were willing to accept genetic testing.Most of the respondents would accept inexpensive early genetic screening.For the genetic testing with higher prices,only 37.9％ of them would accept it.Supposing a positive genetic testing result,most of them were willing to perform prevention through close follow-upscreening,31.3％ of them would choose prophylactic surgery or drugs.Despite being told the confidentiality of the test results,32.9％ of them worried about the adverse effects of genetic test.Conclusions Most of the blood relatives of breast cancer patients were unaware of counseling and genetic testing,but had apparent willingness to accept them.Misunderstanding of genetic characteristics,costs and concerning about discrimination are obstacles for the respondents to accept genetic counseling,genetic testing and related screening prevention.
RESUMEN
Objective To investigate the prevalence of BRCA1/2 gene mutations among Uygur and Han sporadic breast cancer patients in Xinjiang Uygur Automous.Methods Polymerase chain reaction ( PCR) and DNA se-quencing was used to detect mutations of BRCA1(exons 2, 11(11A and 11B) and 20) and BRCA2(exon 11) genes in the Paraffin imbedding tissues from 230 sporadic breast cancer patients ( 115 Uygur and 115 Han ) in Xinjiang Uygur Automous.Results In the 230 cases of sporadic breast cancer patients, 16 cases have gene mu-tation ( 16/230 ,6.96%) .One case of BRCA1 gene in 16 cases of mutations -5 382 locus mutation and 7 cases of new mutations.There was 2 germline mutation in exon 11 of BRCA2 gene.BRCA gene mutation rates of Uygur and Han patients were 7.83% ( 9/115 ) and 6.09% ( 7/115 ) .The onset age of mutations group were 50 or less.Mutations group of patients with amenorrhea ( 3 ) were less than whom were premenopausal ( 13 ) ( P <0.05 ) .Conclusions The prevalence of BRCA1 mutations was significantly higher than BRCA2 in sporadic breast cancer patients of Xinjiang.
RESUMEN
PURPOSE: Options for BRCA mutation carriers include close surveillance, chemoprevention, and risk-reducing surgery (RRS) for breast and ovarian cancer. However, chemoprevention and RRS for cancer prevention are not widely performed in Korea. The aim of this study was to investigate the usage patterns of surveillance, chemoprevention and RRS of breast and ovary in Korean BRCA mutation carriers. METHODS: We retrospectively reviewed the medical record of 67 women who were diagnosed with BRCA1 or BRCA2 mutation between January 2005 and May 2009 at Seoul National University Bundang Hospital. RESULTS: Mean age was 46 years old (range, 27-73 years), and median follow-up period was 10 months. The numbers of affected and unaffected carriers were 50 (74.6%) and 17 (25.4%). In 47 women affected with breast cancer excluding 3 cases of concurrent breast/ovarian cancers, 42 (89.4%) have received intensive surveillance only, 2 (4.3%) have taken tamoxifen for chemoprevention, and 3 (6.4%) have undergone contralateral prophylactic mastectomies to prevent breast cancer. For ovarian cancer prevention, risk reducing salpingo-oophorectomy was performed in 11 (24.4%) of 45 affected carriers excluding 5 patients who had bilateral salphingo-oophorectomy previously. In 17 unaffected carriers, chemoprevention and RRS were not performed. Only 4 (23.5%) of these unaffected carriers have chosen surveillance for breast or ovarian cancer. Old age and no family history are related to the poor compliance (no follow-up) of the carriers only in the univariate analysis but not in the multivariate analysis. CONCLUSION: Most of the Korean affected BRCA mutation carriers in our study chose intensive surveillance rather than chemoprevention or RRS. We should take special effort to follow and educate unaffected carriers, especially for those with old age or no family history.
Asunto(s)
Femenino , Humanos , Neoplasias de la Mama , Neoplasias OváricasRESUMEN
PURPOSE: Few studies have reported ovarian cancer risks in Korean patients with the BRCA1/2 mutation. We investigated the prevalence of ovarian cancer in Korean women at high risk for hereditary breast-ovarian cancer (HBOC) syndrome and reviewed the clinicopathological factors of ovarian cancer. METHODS: Female subjects who were enrolled in the Korean Hereditary Breast Cancer study were included. The questionnaire included a personal and family history of cancer. The BRCA1/2 mutation and CA-125 level were tested at the time of enrollment. A transvaginal ultrasonogram (TVUS) was recommended for subjects with an elevated CA-125 level. RESULTS: A total of 1,689 patients were included. No ovarian cancer was newly diagnosed by CA-125 level or TVUS during the enrollment. The prevalence of ovarian cancer was 1.71% in BRCA1/2 mutation carriers and 0.39% in non-carriers. Among 11 patients with ovarian cancer, five had the BRCA1 mutation and one had the BRCA2 mutation. The most common histopathological type was serous cystadenocarcinoma. No difference in clinicopathological findings between BRCA1/2 mutation carriers and non-carriers was observed. CONCLUSION: The prevalence of ovarian cancer was 58-fold elevated in women at high-risk for HBOC syndrome and 146-fold elevated in the BRCA1 subgroup, compared with the Korean general population. Further investigation with a long-term follow-up is required to evaluate BRCA1/2 gene penetrance.
Asunto(s)
Femenino , Humanos , Neoplasias de la Mama , Neoplasias OváricasRESUMEN
PURPOSE: Sharing genetic information with family members is important for cancer awareness and prevention. The purpose of this study is to examine disclosure patterns of positive BRCA genetic test results to patients' relatives. MATERIALS AND METHODS: A total of 106 probands who had positive BRCA genetic test results from the Korean Hereditary Breast Cancer Study participated in our study. Subjects were asked whether they had disclosed their genetic test results to first-, second-, and third-degree relatives. Univariate and multivariate analyses were used to identify factors associated with positive result sharing with close and distant relatives. RESULTS: In total, 99 respondents (93.4%) informed at least one at-risk relative of the test result, and they all reported that they had disclosed their genetic test result to a first-degree relative. Communication of test results to other relatives occurred significantly less often, with only 31 of 99 subjects (31.3%) sharing their results with second- or third-degree relatives. In the results of univariate analyses, disclosure of genetic test results to more distant relatives was associated with marital status and months since post-test counseling. The reasons for communication were to provide information about the BRCA-related cancer risk and to recommend the genetic test. CONCLUSION: Most individuals with the BRCA mutation share their test results with first-degree family members; however, these results reach more distant relatives significantly less often. Therefore, it is necessary to encourage patients' communication with extended family members through systematic genetic counseling.
Asunto(s)
Humanos , Mama , Neoplasias de la Mama , Consejo , Encuestas y Cuestionarios , Revelación , Asesoramiento Genético , Estado Civil , Análisis MultivarianteRESUMEN
Purpose : Staging of breast tumor has important implications for treatment and prognosis. This study aims at pinpointing the frequency of each stage among familial and nonfamilial breast cancers. Materials and Methods : Ninety-nine Jordanian females diagnosed with familial and nonfamilial breast cancer between 2000 and 2002 were enrolled in this study All breast cancer cases were staged according to the TNM classification into in situ, early invasive, advanced invasive and metastatic. Results : Forty-three cases were familial breast cancer and 56 were nonfamilial. One female breast cancer was diagnosed with ductal carcinoma in situ (DCIS) cancer. Fifty cases were diagnosed in early stages of invasive breast cancer, of which 31 cases were familial, 29 cases were classified as advanced invasive, where 21 cases were nonfamilial and 19 cases were metastatic stage of breast cancer, with 16 nonfamilial cases. Stage 2b was the most common stage of early invasive cases and represented 48% of the early stage of breast cancer. On the other hand, among cases diagnosed with advanced invasive breast cancer, stage 3a was the most common stage and represented 89.6% of the advanced stage. Interestingly, all cases of stage 3a belonged to TNM stages of T2N2M0 and T3N1M0. The tumor size in all cases of Jordanian females diagnosed with advanced invasive breast cancer exceeded 2 cm in size due to selection bias from symptomatic women in our study. Conclusion : The incidence of nonfamilial breast cancer was slightly higher than that of the familial type amongst studied the Jordanian females studied. The early invasive stage of breast cancer was more common in the familial while the advanced invasive and metastatic breast cancer cases were encountered more often in the nonfamilial type. Our study was based on a small sample and symptomatic women. Therefore, more research with larger population samples is needed to confirm this conclusion.
Asunto(s)
Adulto , Anciano , Neoplasias de la Mama/clasificación , Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/patología , Carcinoma Intraductal no Infiltrante/patología , Carcinoma Lobular/patología , Femenino , Humanos , Incidencia , Jordania , Metástasis Linfática , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Adulto JovenRESUMEN
Ovarian cancer is the most lethal cause of death from gynecological malignancies in the Western world. Over 90% of human ovarian cancers arise in the ovarian surface epithelium (OSE). The OSE surrounding the ovary is simple mesothelium and squamous to flat-cubobidal mesothelial cells. This cell type of ovary has both epithelial and mesenchymal potential. Also OSE cells are regulated by many factors such as cytokines, growth factors, and multiple hormones. Nevertheless OSE function is poorly understood. In particular, ovarian cancers are closely related with hereditary predisposition. Hereditary ovarian tumors are commonly associated with mutations in tumor suppressor genes such as brca1 and brca2 genes. These genes play a role in maintenance of genome integrity, DNA repair, cell cycle control and apoptosis. Mutations in brca1 and/or brca2 may lead to carcinogenesis through distinct molecular pathways like estrogen-mediated proliferation, the presence of a p53 mutation, and the modulation of the activity of NF-kB. Especially the dysfunction of brca1 triggers the inactivation of p53 and a higher proportion of a p53 mutation is commonly linked to brca-linked ovarian tumorigenesis. The dysfunction of brca1 and/or brca2 can arise from multiple mechanisms in the regulation of both JNK and ERK1/2 signaling. For more effective diagnosis and therapy of ovarian cancer, the role of brca1 and/or brca2 in ovarian cancer has to be distinctively elucidated by the animal models in which the gene functions are deleted in mouse OSE cells and by the mechanisms by which these genes affect ovarian carcinogenesis.
Asunto(s)
Animales , Femenino , Humanos , Ratones , Apoptosis , Causas de Muerte , Puntos de Control del Ciclo Celular , Transformación Celular Neoplásica , Citocinas , Reparación del ADN , Epitelio , Genes BRCA2 , Genes Supresores de Tumor , Genoma , Péptidos y Proteínas de Señalización Intercelular , Modelos Animales , FN-kappa B , Neoplasias Ováricas , Ovario , Mundo OccidentalRESUMEN
PURPOSE: Women with breast cancer diagnosed at an age of 40 years or younger have a greater prevalence of germline BRCA1 and BRCA2 mutations than the prevalence of women with breast cancer diagnosed at older ages. Several immunohistochemical characteristics have been identified in breast cancers from studies of Caucasian women with BRCA1/2 mutations having familial or early-onset breast cancers. The aim of this study is to determine whether early-onset breast cancer in BRCA1 or BRCA2 mutation carriers, who were not selected from a family history, could be distinguished by the use of immunohistochemical methods and could be distinguished from breast cancer in women of a similar age without a germline BRCA1 or BRCA2 mutation. We also analyzed the prognostic difference between BRCA1/2 related and BRCA1/2 non-related patients by the use of univariate and multivariate analysis. MATERIALS AND METHODS: Breast cancer tissue specimens from Korean women with early-onset breast cancers were studied using a tumor tissue microarray. Immunohistochemical staining of estrogen receptor (ER), progesterone receptor (PR) and HER-2, as well as the histology and grade of these specimens, were compared. The prognostic impact of immunohistochemical and histological factors as well as the BRCA1/2 mutation status was investigated separately. RESULTS: There were 14 cases and 16 deleterious BRCA1/2 mutations among 101 patients tested. A family history (4/14) and bilateral breast cancers (3/9) were high risk factors for BRCA1/2 mutations. BRCA1/2- associated cancers demonstrated more expression of ER-negative (19.4% versus 5.1%, p=0.038) and HER-2 negative than BRCA1/2 negative tumors, especially for tumors with BRCA1 tumors The BRCA1/2 mutation rate for patients with triple negative tumors (negative expression of ER, PR and HER-2) was 24.2%. Tumor size, nodal status, and HER-2 expression status were significantly associated with disease free survival, as determined by univariate and multivariate analysis, but the BRCA1/2 status was not a prognostic factor. CONCLUSION: Breast cancer that occurs in women with a germline BRCA1 or BRCA2 mutations have recognizable immunohistochemical features, which may be useful in identifying individuals that are more likely to carry germline mutations. Although the BRCA1/2 mutation status was not a prognostic factor in Korean women with early-onset breast cancer, more cases with a longer follow-up period are needed for further study.